Date: 5.8.2014
Technology offer: Anticancer agents based on human pancreatic ribonuclease
Reference: 13 ES 252K 3SRH
Summary: A Catalan research group has developed a new anticancer therapy directed against nuclear RNA based on the engineering of human pancreatic ribonuclease. These ribonucleases are non-genotoxic drugs and it is thought very difficult that they may generate drug resistance phenotype. Their human origin warrants poor or null immunogenicity in clinical uses. License agreement or a technology development agreement with companies is sought.
For more information click here.
Technologické nabídky a poptávky zpracovává BIC Plzeň, partner sítě Enterprise Europe Network.
Gate2Biotech - Biotechnology Portal - All Czech Biotechnology information in one place.
ISSN 1802-2685
This website is maintained by: CREOS CZ
© 2006 - 2024 South Bohemian Agency for Support to Innovative Enterprising (JAIP)
Interesting biotechnology content:
Cancer cells - Czech Scientists are Working to Find the Achilles‘ Heel of Cancer Cells
Biotechnology projecst no.10 - 10th page of our biotechnology projects database
More than 100 magic mushroom genomes point the way to new cultivars
Gene-edited pig kidney transplanted into first living human patient